Advertisement
Canada markets open in 7 hours 33 minutes

  • S&P/TSX

    21,788.48
    -60.11 (-0.28%)
     

  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     

  • DOW

    39,112.16
    -299.05 (-0.76%)
     

  • CAD/USD

    0.7321
    -0.0002 (-0.03%)
     

  • CRUDE OIL

    81.27
    +0.44 (+0.54%)
     

  • Bitcoin CAD

    84,210.85
    +848.05 (+1.02%)
     

  • CMC Crypto 200

    1,278.02
    +28.90 (+2.31%)
     

  • GOLD FUTURES

    2,324.90
    -5.90 (-0.25%)
     

  • RUSSELL 2000

    2,022.35
    -8.47 (-0.42%)
     

  • 10-Yr Bond

    4.2380
    -0.0100 (-0.24%)
     

  • NASDAQ futures

    20,010.50
    +38.25 (+0.19%)
     

  • VOLATILITY

    12.84
    -0.49 (-3.68%)
     

  • FTSE

    8,247.79
    -33.76 (-0.41%)
     

  • NIKKEI 225

    39,685.70
    +512.55 (+1.31%)
     

  • CAD/EUR

    0.6837
    +0.0005 (+0.07%)
     

Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Business Wire
·1 min read

CAMBRIDGE, Mass., June 05, 2024--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 2:00 p.m. ET in Miami, FL.

A live webcast of the presentation can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics
Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at www.sagerx.com or engage with us on Facebook, LinkedIn, Instagram, and X.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20240605254101/en/

Contacts

Investor Contact
Ashley Kaplowitz
786-252-1419
ashley.kaplowitz@sagerx.com

Media Contact
Matthew Henson
917-930-7147
matthew.henson@sagerx.com